Fondazione FIRMO Onlus (Fondazione Italiana Ricerca Sulle Malattie Dell'Osso), F.I.R.M.O. Foundation, Via San Gallo, 123, 50129, Florence, Italy.
Geriatric Unit, Azienda Sanitaria Toscana Centro, Florence, Italy.
Geroscience. 2024 Dec;46(6):6141-6156. doi: 10.1007/s11357-024-01193-1. Epub 2024 Jun 5.
Few studies have evaluated the association between circulating levels of 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D (1,25(OH)D), and the endocrine disruptor bisphenol A (BPA), with risk of cardiovascular (CV) disease in elderly individuals. This was a cross-sectional study in a subgroup of elderly people from the InCHIANTI Biobank in Italy. We examined the association between circulating serum vitamin D metabolites, 1,25(OH)D, 25(OH)D, and the endocrine disrupting agent BPA, with an arbitrary CV risk score and the European Society of Cardiology-based 10-year CV risk (SCORE2/SCORE2-OP) using univariate and multiple regression. In 299 individuals, blood samples were tested for serum values of 25(OH)D, 1,25(OH)D and urinary BPA levels. One hundred eighty individuals (60.2%) were deficient (< 20 ng/ml) in 25(OH)D. Levels of 25(OH)D and 1,25(OH)D were negatively correlated with CV risk score (p < 0.0001 for both) as well as SCORE2/SCORE2-OP (p < 0.0001 for both) while BPA levels were positively correlated with both CV risk scores (p < 0.0001 for both). In a logistic regression model, male gender (odds ratio; OR: 2.1, 95% CI:1.1-3.8, p = 0.022), obesity (OR:2.8, 95% CI:1.2-6.5, p = 0.016) and BPA levels ≥ 110 ng/dl (OR:20.9, 95% CI:9.4-46.8, p < 0.0001) were associated with deficient levels of 25(OH)D. 1,25(OH)2D levels < 41 ng/dl and 25(OH)D levels < 20 ng/ml were associated with CV risk score ≥ 3 (OR: 4.16, 95% CI: 2.32-7.4, p < 0.0001 and OR: 1.86, 95% CI: 1.02-3.39, p = 0.044) respectively and 1,25(OH)2D levels < 41 ng/dl were associated with SCORE2/SCORE2-OP of ≥ 20% (OR:2.98, 95% CI: 1.7-5.2, p = 0.0001). In this cross-sectional analysis, BPA exposure was associated with significantly reduced levels of vitamin D that in turn were significantly associated with increased CV risk.
很少有研究评估循环 25-羟维生素 D(25(OH)D)、1,25-二羟维生素 D(1,25(OH)D)和内分泌干扰物双酚 A(BPA)水平与老年人心血管(CV)疾病风险之间的关系。这是意大利 InCHIANTI 生物库中老年人的一项横断面研究。我们使用单变量和多元回归分析了循环血清维生素 D 代谢物、1,25(OH)D、25(OH)D 和内分泌干扰物 BPA 与任意 CV 风险评分和基于欧洲心脏病学会的 10 年 CV 风险(SCORE2/SCORE2-OP)之间的关系。在 299 名个体中,检测了血清 25(OH)D、1,25(OH)D 和尿 BPA 水平。180 名个体(60.2%)血清 25(OH)D 缺乏(<20ng/ml)。25(OH)D 和 1,25(OH)D 水平与 CV 风险评分呈负相关(均 p<0.0001),与 SCORE2/SCORE2-OP 呈负相关(均 p<0.0001),而 BPA 水平与 CV 风险评分均呈正相关(均 p<0.0001)。在逻辑回归模型中,男性(比值比;OR:2.1,95%CI:1.1-3.8,p=0.022)、肥胖(OR:2.8,95%CI:1.2-6.5,p=0.016)和 BPA 水平≥110ng/dl(OR:20.9,95%CI:9.4-46.8,p<0.0001)与 25(OH)D 缺乏有关。1,25(OH)2D 水平<41ng/dl 和 25(OH)D 水平<20ng/ml 与 CV 风险评分≥3 相关(OR:4.16,95%CI:2.32-7.4,p<0.0001 和 OR:1.86,95%CI:1.02-3.39,p=0.044),1,25(OH)2D 水平<41ng/dl 与 SCORE2/SCORE2-OP≥20%相关(OR:2.98,95%CI:1.7-5.2,p=0.0001)。在这项横断面分析中,BPA 暴露与维生素 D 水平显著降低有关,而维生素 D 水平又与 CV 风险增加显著相关。